Aura Biosciences develops bel sar, an experimental cancer drug for eye and bladder tumors that is still in clinical trials. It last closed at $7.15 on Nov 17, down 0.97% on the day. In the past 30 days there were 1 dark pool print totaling $261K, the largest $261K.
AURA · as of the Nov 17 close · updated after every close
Uptrend
The stock is 6% above its 20 day and 9% above its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the swing low (Aug 12) at $7.07, and the nearest resistance the Pivot R1 at $7.30.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.4%/day
Key levels
$9.5452 week high+33.4%
$7.31Swing high (Jul 27)+2.2%
$7.30Pivot R1+2.1%
$7.15Pivot+0.0%
$7.15Last close
$7.07Swing low (Aug 12)−1.1%
$7.00Pivot S1−2.1%
$6.94100 day average−2.9%
$6.80200 day average−4.9%
$6.6920 day average−6.4%
$6.5350 day average−8.7%
$4.7352 week low−33.8%
Indicators
RSI (14)
57.41
Middle of its range
Neutral
MACD
0.22
Above its signal line
Bullish
Stochastic
62.0
Middle of its range
Neutral
ADX (14)
20.3
Weak trend
Williams %R
-38.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
71.7
Oversold below −100, overbought above 100
Neutral
Rate of change
+14.6%
Change over 10 sessions
Bullish
ATR (14)
$0.38
Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 10.5%/day
Key levels
$9.5452 week high+33.4%
$7.31Swing high (Jul 27)+2.2%
$7.30Pivot R1+2.1%
$7.15Pivot+0.0%
$7.15Last close
$7.07Swing low (Aug 12)−1.1%
$7.00Pivot S1−2.1%
$6.94100 day average−2.9%
$6.80200 day average−4.9%
$6.6920 day average−6.4%
$6.5350 day average−8.7%
$4.7352 week low−33.8%
Indicators
RSI (14)
54.21
Middle of its range
Neutral
MACD
-0.04
Below its signal line
Bearish
Stochastic
42.6
Middle of its range
Neutral
ADX (14)
21.9
Weak trend
Williams %R
-49.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
32.2
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.1%
Change over 10 sessions
Bullish
ATR (14)
$0.75
Typical daily range, 10.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for AURA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow AURA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AURA is in one of them and how their past AURA trades turned out.
Aura Biosciences is a biotechnology company developing drugs to treat solid tumors while aiming to preserve organ function. Its lead candidate, bel sar, is in later stage clinical trials for early choroidal melanoma, a rare eye cancer, and is also being tested in other eye cancers and in bladder cancer. Bel sar is built from modified human papilloma virus proteins linked to molecules that are activated by light, and it has not yet been approved for sale. The company is based in Boston, Massachusetts, and its intended patients are adults with these cancers.